Jonathan E Brammer, MD
Academic Title: Associate Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI’m a hematologist specializing in patients with T-cell lymphoma, T-cell leukemia, non-Hodgkin lymphoma, and allogenic and autologous stem cell transplantation. I received my medical training at Northeastern Ohio Universities College of Medicine, and I completed my residency at the Baylor College of Medicine. I then completed fellowships in hematology/oncology at Oregon Health and Sciences University and MD Anderson Cancer Center, where I spent a year as a faculty clinical researcher. My research focuses on T-cell lymphoma and leukemia, as well as cellular therapy, including stem cell transplantation. I also serve as an assistant professor in Internal Medicine at The Ohio State University. My research has been published in numerous journals, including: Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation and Leukemia and Lymphoma. What I love about working at the OSUCCC – James is the collaboration between skilled medical professionals. The James fosters an environment that thrives on research, and working with such skilled colleagues makes me a better physician. I also love the opportunity to help my patients through one of the most difficult times in their lives. I believe that through research, cutting-edge technology and targeted care plans, we can work toward a cancer-free world and more hopeful outcomes for our patients.
Clinical Expertise
More info for- Non-Hodgkin Lymphoma
- Lymphoma, T-Cell, Cutaneous
- Hematology
- Stem Cell Transplantation
- Hodgkin Lymphoma
- Bone Marrow Transplantation
- Leukemia
Where I See Patients
More info forEducation & Training
More info forInternship - Internal Medicine
- Baylor College of Medicine
1 Baylor Plz, Houston, TX
Residency - Internal Medicine
- Baylor College of Medicine
1 Baylor Plz, Houston, TX
Medical School
- Northeast Ohio Medical University
Po Box 95, Rootstown, OH
Fellowship - Hematology & Oncology
- Oregon Health Sciences University
3181 Sw Sam Jackson Park Rd, Portland, OR
Fellowship - Hematology & Oncology
- University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX
- Baylor College of Medicine
Academic Office & Contact Information
More info forAcademic Office:
The James Outpatient Care 7168
2121 Kenny Rd
Columbus, Ohio 43221Email:
brammer.44@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 19, 2024Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas.
Braunstein Z, Brammer JE
Curr Hematol Malig Rep
October 12, 2024Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.
Caputo J, Peddireddi A, Bhatta S, Huang Y, Bezerra E, Brammer J, Larkin K, Mims A, Vasu S, Wall S, Choe H
Leuk Lymphoma
August 31, 2024ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.
Goyal A, O'Leary D, Dabaja B, Weng WK, Zain J, Cutler C, Guitart J, Kim YH, Geskin LJ, Hoppe RT, Wilson LD, Beaven AW, Horwitz S, Allen PB, Barta SK, Bohjanen K, Brammer JE, Carter JB, Comfere N, DeSimone JA, Dusenbery K, Duvic M, Huen A, Jagadeesh D, Kelsey CR, Khodadoust MS, Lechowicz MJ, Mehta-Shah N, Moskowitz AJ, Olsen EA, Poh C, Pro B, Querfeld C, Sauter C, Sokol L, Sokumbi O, Wilcox RA, Zic JA, Hamadani M, Foss F
Transplant Cell Ther
August 19, 2024Representation of women in clinical trials supporting FDA-approval of contemporary cancer therapies.
Kalathoor S, Ghazi S, Otieno B, Babcook MA, Chen S, Nidhi N, Bae J, Pierre-Charles J, Breathett K, Mazimba S, Johnson A, Brewer L, Mohammed S, Carter RR, Bonsu JM, Ferdousi M, Kola-Kehinde O, McLaughlin E, Brammer J, Ruz P, Khan S, Odei B, Mitchell D, Wei L, Patel P, Paskett ED, Addison D
Int J Cancer
July 24, 2024Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.
Herrera AF, Zain J, Savage KJ, Feldman T, Brammer JE, Chen L, Puverel S, Popplewell L, Budde LE, Mei M, Hosing C, Nair R, Leslie L, Daniels S, Peters L, Forman S, Rosen S, Kwak L, Iyer SP
Lancet Haematol
July 22, 2024Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample.
Krishan S, Asad ZUA, Quiroga D, Ghazi SM, Quartermaine C, Braunstein Z, Kola-Kehinde O, Shaaban A, Habib A, Khan S, Cheng R, Brammer JE, Addison D
Sci Rep
July 8, 2024Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.
Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M
Blood Cancer J
May 30, 2024Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib.
Risch Z, Kaffenberger BH, Chung CG, Samorodnitsky E, Hoskins EL, Dao T, Smith A, Wall SA, Brammer J, Reeser JW, Wing MR, Hopkins JF, Albacker LA, Abruzzo LV, Eisele CD, Freud AG, Roychowdhury S, Walsh KE
Haematologica
May 13, 2024The CNS Relapse in T-Cell Lymphoma Index Predicts CNS Relapse in Patients with T- and NK-Cell Lymphomas.
Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver RN, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez JC, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain J, Ruiz M, Brammer JE, Prakash R, Padmanabhan Iyer S, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos BM, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Jagadeesh D, Brooks TR, Hariharan N, Goodman AM, Hartmann G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK
Blood Adv
March 23, 2024Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.
Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, Wu D, Chan WK, Bezerra ED, Epperla N, Voorhees TJ, Brammer JE, Kittai AS, Bond DA, Sawalha Y, Sigmund AM, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks KJ, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski SM, Li Z, Huang X, Yang Y
Blood Adv
February 29, 2024A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.
Moustafa MA, Ramdial JL, Tsalatsanis A, Khimani F, Dholaria B, Bojanini L, Brooks T, Zain J, Bennani NN, Braunstein Z, Brammer JE, Beitinjaneh A, Jagadeesh D, Weng WK, Kumar A, Kharfan-Dabaja MA, Ahmed S, Murthy HS
Transplant Cell Ther
December 13, 2023Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas.
Braunstein Z, Waller A, Dotson E, McLaughlin E, Hanel W, Reneau J, Addison D, Porcu P, Brammer JE
Leuk Lymphoma
August 2, 2023Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study.
Haverkos BM, Alpdogan O, Baiocchi RA, Brammer JE, Feldman T, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill SE, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P
Blood Adv
June 23, 2023Effective Treatment with the Selective Cytokine Inhibitor BNZ-1 Reveals the Cytokine Dependency of T-LGL Leukemia.
Brammer JE, Ballen K, Sokol L, Querfeld C, Nakamura R, Mishra A, Mclaughlin EM, Feith D, Azimi N, Waldmann T, Tagaya Y, Loughran T
Blood
April 1, 2023Atrial Fibrillation With Modern Cancer Treatment: More Common Than We Think.
Addison D, Quartermaine C, Brammer JE
JACC CardioOncol
March 29, 2023Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasms.
Isabelle C, Johnson WT, McConnell K, Vogel A, Brammer JE, Boles A, Keller R, Sindaco P, Nisenfeld L, Uppal G, Nikbakht N, Calabretta B, Porazzi P, Gong JZ, Chakravarti N, Porcu P, Mishra A
Blood Adv
February 24, 2023A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L
Cancers (Basel)
January 1, 2023The role of interleukin-15 in the development and treatment of hematological malignancies.
Sindaco P, Pandey H, Isabelle C, Chakravarti N, Brammer JE, Porcu P, Mishra A
Front Immunol
November 14, 2022Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Cancers (Basel)
October 26, 2022Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy.
Annunzio K, Cackovic M, Bond DA, Sawalha Y, Voorhees TJ, Hanel W, Alinari L, Baiocchi RA, Reneau JC, Brammer JE, Maddocks K, Christian B, Epperla N
Blood Adv
June 13, 2022Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.
Braunstein Z, Ruiz M, Hanel W, Shindiapina P, Reneau JC, Brammer JE
J Pers Med
May 10, 2022Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions.
Reneau JC, Shindiapina P, Braunstein Z, Youssef Y, Ruiz M, Farid S, Hanel W, Brammer JE
J Clin Med
March 3, 2022Assessment of Salvage Regimens Post CAR-T Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma.
Sigmund AM, Denlinger N, Huang Y, Bond D, Voorhees T, Bajwa A, Elder P, Brammer JE, Saad A, Penza S, Vasu S, de Lima M, Jaglowski S, Kittai AS
Transplant Cell Ther
March 1, 2022Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.
Mundy-Bosse BL, Weigel C, Wu YZ, Abdelbaky S, Youssef Y, Casas SB, Polley N, Ernst G, Young KA, McConnell KK, Nalin AP, Wu KG, Broughton M, Lordo MR, Altynova E, Hegewisch-Solloa E, Enriquez-Vera DY, Dueñas D, Barrionuevo C, Yu SC, Saleem A, Suarez CJ, Briercheck EL, Molina-Kirsch H, Loughran TP, Weichenhan D, Plass C, Reneau JC, Mace EM, Gamboa FV, Weinstock DM, Natkunam Y, Caligiuri MA, Mishra A, Porcu P, Baiocchi RA, Brammer JE, Freud AG, Oakes CC
Blood Cancer Discov
March 1, 2022T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H
J Natl Compr Canc Netw
February 3, 2022Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
Bajwa A, Huang Y, Li R, Denlinger N, Brammer J, Penza S, Saad A, Jaglowski S, Kittai AS
Leuk Lymphoma
February 2, 2022Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M
Br J Haematol
January 7, 2022Cyclophosphamide Induces Durable Molecular and Clinical Responses in Patients with Relapsed T-LGL Leukemia.
Braunstein Z, McLaughlin E, Mishra A, Brammer JE
Blood Adv
January 1, 2022Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant.
Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Front Oncol
January 1, 2022Cytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia.
Isabelle C, Boles A, Chakravarti N, Porcu P, Brammer J, Mishra A
Front Oncol
January 1, 2022Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias.
Braunstein Z, McLaughlin E, Ruiz M, Wei L, Bumma N, Benson D, Devarakonda S, Chaudhry M, Khan A, Cottini F, Hanel W, Baiocchi R, Chung C, Addison D, Couette N, Meara A, Jarjour W, Porcu P, Mishra A, Reneau JC, Rosko AE, Brammer JE
Front Oncol
January 1, 2022Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease.
Couette N, Jarjour W, Brammer JE, Simon Meara A
Front Oncol
January 1, 2022Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study.
Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha Y
Ther Adv Hematol
January 1, 2022Editorial: Pathogenesis, treatment, and future directions for rare T-cell leukemias.
Herling M, Jarjour W, Mishra A, Brammer JE
Front Oncol
December 21, 2021Acute GVHD, BK hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults.
Vasu S, Bostic MG, Zhao Q, Sharma N, Puto M, Knight S, Scott D, Guzman R, Kromer M, Tackett K, Lind KE, Knill K, Watson E, Wall SA, Saad A, Choe HK, Larkin K, Brammer JE, Jaglowski SM, Penza S, Davies SM, Cataland SR
Blood Adv
November 17, 2021Feasibility of High-dose Methotrexate Administered on Day 1 of (R)CHOP in aggressive non-Hodgkin Lymphomas.
Fleming MK, Huang Y, Dotson EK, Bond DA, Reneau JC, Epperla N, Alinari L, Brammer JE, Christian B, Baiocchi RA, Maddocks K, Sawalha Y
Blood Adv
September 30, 2021Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies.
Bonsu JM, Kola-Kehinde O, Kim L, Ruz P, Campbell CM, Brammer JE, Addison D
JAMA Oncol
August 1, 2021Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D
J Immunother Cancer
July 24, 2021Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, Ruan J, Porcu P, Brammer JE, Jacobsen ED, Yoon DH, Suh C, Suarez F, Radford J, Budde LE, Kim JS, Bachy E, Lee HJ, Bollard CM, Jaccard A, Kang HJ, Inman S, Murray M, Combs KE, Lee DY, Advani R, Gunter KC, Rooney CM, Heslop HE
Ann Hematol
January 1, 2021Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience.
Schaefer A, Huang Y, Kittai A, Maakaron JE, Saygin C, Brammer J, Penza S, Saad A, Jaglowski SM, William BM
Cancer Manag Res
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Brammer has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Kymera
- Dren Bio
- Vittoria Biotherapeutics
Patient Comments
The providers were very knowledgeable of course and I felt some type of relief during my appointment.
My oncologist took my through my illness because of his vast knowledge and experience
I feel very lucky to have these professionals taking care of my health.
Dr. Brammer is fantastic.
I am very lucky to have Dr Brammer. He is very concerned with details never overlooks any nuances. He is concerned with my body but has empathy for me feelings.
Dr Brammer is the BEST
EXCELLENT !!!
All are top notch, especially Dr. Brammer.